Cytokine and immune system abnormalities in fibromyalgia and other central sensitivity syndromes

Current Rheumatology Reviews

Volumn 11, Issue 2, 2015, Pages 109-115

  Staud, Roland ^a  

^a Department of Medicine ^*  (United States)

Author keywords

Central sensitivity; Central sensitivity syndromes; Clinical pain; Cytokines; Inflammation

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; CALCITONIN GENE RELATED PEPTIDE; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANALGESIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM SENSITIZATION; CENTRAL SENSITIVITY SYNDROME; CHRONIC FATIGUE SYNDROME; CHRONIC PAIN; DISEASES; FIBROMYALGIA; GLIA CELL; HUMAN; IMMUNOPATHOLOGY; IRRITABLE COLON; NATURAL KILLER CELL; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; TEMPOROMANDIBULAR JOINT DISORDER; TH1 CELL; TH17 CELL; CENTRAL NERVOUS SYSTEM; IMMUNE SYSTEM; METABOLISM;

CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM SENSITIZATION; CHRONIC PAIN; CYTOKINES; FATIGUE SYNDROME, CHRONIC; FIBROMYALGIA; HUMANS; IMMUNE SYSTEM; IRRITABLE BOWEL SYNDROME; NEUROTRANSMITTER AGENTS; RECEPTORS, CYTOKINE;

EID: 84937133309     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/1573397111666150619094819     Document Type: Article

References (112)

1. Dinarello CA. Historical insights into cytokines. Eur J Immunol 2007; 37: S34-S45.
2. Bowen RA, Hortin GL, Csako G, et al. Impact of blood collection devices on clinical chemistry assays. Clin Biochem 2010; 43: 4-25.
3. Bowen RA, Remaley AT. Interferences from blood collection tube components on clinical chemistry assays. Biochem Med (Zagreb) 2014; 24: 31-44.
4. Keustermans GC, Hoeks SB, Meerding JM, et al. Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples. Methods 2013; 61: 10-7.
5. de Jager W, Bourcier K, Rijkers GT, et al. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 2009; 10: 52-10.
6. Parkitny L, McAuley JH, Kelly PJ, et al. Multiplex cytokine concentration measurement: how much do the medium and handling matter? Mediators Inflamm 2013; 2013: 890706.
7. Skogstrand K, Ekelund CK, Thorsen P, et al. Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples. J Immunol Methods 2008; 336: 78-84.
8. Khan SS, Smith MS, Reda D, et al. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom 2004; 61: 35-9.
9. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004; 361: 184-7.
10. Uceyler N, Schafers M, Sommer C. Mode of action of cytokines on nociceptive neurons. Exp Brain Res 2009; 196: 67-78.
11. Inui A. Cytokines and sickness behavior: implications from knockout animal models. Trends Immunol 2001; 22: 469-73.
12. Staud R, Vierck CJ, Cannon RL, et al. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001; 91: 165-75.
13. Staud R, Robinson ME, Price DD. Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J Pain 2007; 8: 893- 901.
14. Staud R. Abnormal pain modulation in patients with spatially distributed chronic pain: Fibromyalgia. Rheum Dis Clin North Am 2009; 35: 263-74.
15. Staud R. Is it all central sensitization? Role of peripheral tissue nociception in chronic musculskeletal pain. Curr Rheumatol Rep 2010; 12: 448-54.
16. Staud R. Objective biomarkers or symptom scores for the classification of fibromyalgia syndrome? Curr Rheum Rev 2012; 8: 307-17.
17. Staud R, Weyl EE, Riley JL, III, et al. Slow temporal summation of pain for assessment of central pain sensitivity and clinical pain of fibromyalgia patients. PLoS One 2014; 9: e89086.
18. McCrone P, Darbishire L, Ridsdale L, et al. The economic cost of chronic fatigue and chronic fatigue syndrome in UK primary care. Psychol Med 2003; 33: 253-61.
19. Knight T, Schaefer C, Chandran A, et al. Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clinicoecon Outcomes Res 2013; 5: 171-80.
20. Scholz J, Woolf CJ. The neuropathic pain triad: Neurons, immune cells and glia. Nat Neurosci 2007; 10: 1361-8.
21. Ji RR, Berta T, Nedergaard M. Glia and pain: Is chronic pain a gliopathy? Pain 2013; 154: S10-S28.
22. Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 2009; 32: 421-31.
23. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nature Reviews Neuroscience 2005; 6: 521-32.
24. Bazzichi L, Rossi A, Massimetti G, et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007; 25: 225-30.
25. Ross RL, Jones KD, Bennett RM, et al. Preliminary Evidence of Increased Pain and Elevated Cytokines in Fibromyalgia Patients with Defective Growth Hormone Response to Exercise. Open Immunol J 2010; 3: 9-18.
26. Wang HL, Moser M, Schiltenwolf M, et al. Circulating cytokine levels compared to pain in patients with fibromyalgia - A prospective longitudinal study over 6 months. J Rheumatol 2008; 35: 1366-70.
27. Lorusso L, Mikhaylova SV, Capelli E, et al. Immunological aspects of chronic fatigue syndrome. Autoimmunity Reviews 2009; 8: 287-91.
28. Patarca R. Cytokines and chronic fatigue syndrome. Ann N Y Acad Sci 2001; 933: 185-200.
29. Patarca R, Klimas NG, Lugtendorf S, et al. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis 1994; 18 Suppl 1: S147-S153.
30. Scully P, McKernan DP, Keohane J, et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal comorbidity. Am J Gastroenterol 2010; 105: 2235-43.
31. Clark AK, Old EA, Malcangio M. Neuropathic pain and cytokines: current perspectives. J Pain Res 2013; 6: 803-14.
32. Wang XM, Hamza M, Wu TX, et al. Upregulation of IL-6, IL-8 and CCL2 gene expression after acute inflammation: Correlation to clinical pain. Pain 2009; 142: 275-83.
33. Uceyler N, Valenza R, Stock M, et al. Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis and Rheumatism 2006; 54: 2656-64.
34. Shah JP, Phillips TM, Danoff JV, et al. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol 2005; 99: 1977-84.
35. Shah JP. Uncovering the biochemical milieu of myofascial trigger points using in vivo microdialysis. J Musculoskelet Pain 2008; 16: 17-20.
36. Gerdle B, Lemming D, Kristiansen J, et al. Biochemical alterations in the trapezius muscle of patients with chronic whiplash associated disorders (WAD) - A microdialysis study. Eur J Pain 2008; 12: 82- 93.
37. Rosendal L, Sogaard K, Kjaer M, et al. Increase in interstitial interleukin-6 of human skeletal muscle with repetitive low-force exercise. J Appl Physiol 2005; 98: 477-81.
38. Helmy A, Carpenter KL, Skepper JN, et al. Microdialysis of cytokines: methodological considerations, scanning electron microscopy, and determination of relative recovery. J Neurotrauma 2009; 26: 549-61.
39. Yunus MB. Central Sensitivity Syndromes: A New Paradigm and Group Nosology for Fibromyalgia and Overlapping Conditions, and the Related Issue of Disease versus Illness. Semin Arthritis Rheum 2008; 37: 339-52.
40. Yunus MB. Central Sensitivity Syndromes: An Overview. J Musculoskelet Pain 2009; 17: 400-8.
41. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011; 152: S2-S15.
42. Woolf CJ. Windup and central sensitization are not equivalent. Pain 1996; 66: 105-8.
43. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009; 10: 895-926.
44. Dickenson AH, Sullivan AF. NMDA receptors and central hyperalgesic states. Pain 1991; 46: 344-6.
45. Wallace DJ, Linker-Israeli M, Hallegua D, et al. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 2001; 40: 743-9.
46. Dantzer R, Bluthe RM, Laye S, et al. Cytokines and sickness behavior. Ann N Y Acad Sci 1998; 840: 586-90.
47. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 2004; 500: 399-411.
48. Kelley KW, Bluthe RM, Dantzer R, et al. Cytokine-induced sickness behavior. Brain Behav Immun 2003; 17: S112-S118.
49. Caro XJ. Is there an immunologic component to the fibrositis syndrome? Rheum Dis Clin North Am 1989; 15: 169-86.
50. Paiva ES, da Costa EDGM, Scheinberg M. Fibromyalgia: An update and immunological aspects. Curr Pain Headache Rep 2008; 12: 321-6.
51. Littlejohn GO, Weinstein C, Helme RD. Increased neurogenic inflammation in fibrositis syndrome. J Rheumatol 1987; 14: 1022- 5.
52. Maes M, Libbrecht I, Van Hunsel F, et al. The immuneinflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology 1999; 24: 371- 83.
53. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheumatol 1994; 37: 1593-601.
54. Russell IJ. Neurochemical pathogenesis of fibromyalgia syndrome. J Musculoskel Pain 1996; 4: 61-92.
55. Kadetoff D, Lampa J, Westman M, et al. Evidence of central inflammation in fibromyalgia - Increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 2012; 242: 33-8.
56. Wingenfeld K, Heim C, Schmidt I, et al. HPA axis reactivity and lymphocyte glucocorticoid sensitivity in fibromyalgia syndrome and chronic pelvic pain. Psychosomatic Medicine 2008; 70: 65-72.
57. Gur A, Oktayoglu P. Status of immune mediators in Fibromyalgia. Curr Pain Headache Rep 2008; 12: 175-81.
58. Dunn AJ. Cytokine activation of the HPA axis. Ann N Y Acad Sci 2000; 917: 608-17.
59. Malcangio M, Bowery NG, Flower RJ, et al. Effect of interleukin-1 beta on the release of substance P from rat isolated spinal cord. Eur J Pharmacol 1996; 299: 113-8.
60. Takahashi S, Kapas L, Fang J, et al. Somnogenic relationships between tumor necrosis factor and interleukin-1. Am J Physiol 1999; 276: R1132-R1140.
61. Wallace DJ. Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Design 2006; 12: 17-22.
62. Papanicolaou DA, Wilder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-37.
63. Uceyler N, Hauser W, Sommer C. Systematic review with metaanalysis: cytokines in fibromyalgia syndrome. BMC Musculoskeletal Disorders 2011; 12.
64. Uceyler N, Valenza R, Stock M, et al. Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheumatol 2006; 54: 2656-64.
65. Kashipaz MRA, Swinden D, Todd I, et al. Normal production of inflammatory cytokines in chronic fatigue and fibromyalgia syndromes determined by intracellular cytokine staining in shortterm cultured blood mononuclear cells. Clin Exp Immunol 2003; 132: 360-5.
66. Bansal AS, Bradley AS, Bishop KN, et al. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun 2012; 26: 24-31.
67. Reid S, Chalder T, Cleare A, et al. Chronic fatigue syndrome. Clin Evid 2002;1075-88.
68. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003; 160: 221-36.
69. Komaroff AL, Cho TA. Role of Infection and Neurologic Dysfunction in Chronic Fatigue Syndrome. Seminars in Neurology 2011; 31: 325-37.
70. Komaroff AL, Buchwald D. Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis 1991; 13 Suppl 1: S8-11.
71. Christley Y, Duffy T, Martin CR. A review of the definitional criteria for chronic fatigue syndrome. Journal of Evaluation in Clinical Practice 2012; 18: 25-31.
72. Reid S, Chalder T, Cleare A, et al. Chronic fatigue syndrome. BMJ 2000; 320: 292-6.
73. Patarca-Montero R, Antoni M, Fletcher MA, et al. Cytokine and other immunologic markers in chronic fatigue syndrome and their relation to neuropsychological factors. Appl Neuropsychol 2001; 8: 51-64.
74. Stewart CC, Cookfair DL, Hovey KM, et al. Predictive immunophenotypes: Disease-related profile in chronic fatigue syndrome. Cytometry 2003; 53B: 26-33.
75. Brenu EW, Hardcastle SL, Atkinson GM, et al. Natural killer cells in patients with severe chronic fatigue syndrome. Autoimmune Highlights 2013; 4: 69-80.
76. Huth TK, Brenu EW, Nguyen T, et al. Characterization of natural killer cell phenotypes in chronic fatigue syndrome/myalgic encephalitis. Clin Cell Immunol 2014; 5: 1-8.
77. Maes M, Twisk FNM, Kubera M, et al. Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-alpha, PMN-elastase, lysozyme and neopterin. J Affect Disord 2012; 136: 933-9.
78. Stringer EA, Baker KS, Carroll IR, et al. Daily cytokine fluctuations, driven by leptin, are associated with fatigue severity in chronic fatigue syndrome: evidence of inflammatory pathology. Journal of Translational Medicine 2013; 11.
79. Anderson G, Berk M, Maes M. Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatr Scand 2013;10.
80. Chia J, Chia A, Voeller M, et al. Acute enterovirus infection followed by myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and viral persistence. J Clin Pathol 2010; 63: 165-8.
81. Kerr JR. Enterovirus infection of the stomach in chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Pathol 2008; 61: 1-2.
82. Dantzer R, Kelley KW. Twenty years of research on cytokineinduced sickness behavior. Brain Behav Immun 2007; 21: 153-60.
83. Buchwald D, Wener MH, Pearlman T, et al. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol 1997; 24: 372-6.
84. Moss RB, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. J Clin Immunol 1999; 19: 314-6.
85. Raison CL, Lin JMS, Reeves WC. Association of peripheral inflammatory markers with chronic fatigue in a population-based sample. Brain Behavior and Immunity 2009; 23: 327-37.
86. Cannon JG, Angel JB, Abad LW, et al. Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol 1997; 17: 253-61.
87. Nijs J, Van Oosterwijck J, Meeus M, et al. Unravelling the nature of postexertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome: the role of elastase, complement C4a and interleukin-1beta. J Intern Med 2010; 267: 418-35.
88. Fletcher MA, Zeng XR, Barnes Z, et al. Plasma cytokines in women with chronic fatigue syndrome. Journal of Translational Medicine 2009; 7.
89. Nater UM, Youngblood LS, Jones JF, et al. Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with chronic fatigue syndrome. Psychosomatic Medicine 2008; 70: 298- 305.
90. Natelson BH, Denny T, Zhou XD, et al. Is depression associated with immune activation? J Affect Disord 1999; 53: 179-84.
91. ter Wolbeek M, van Doornen LJP, Kavelaars A, et al. Longitudinal analysis of pro- and anti-inflammatory cytokine production in severely fatigued adolescents. Brain Behavior and Immunity 2007; 21: 1063-74.
92. Nakamura T, Schwander SK, Donnelly R, et al. Cytokines across the Night in Chronic Fatigue Syndrome with and without Fibromyalgia. Clinical and Vaccine Immunology 2010; 17: 582-7.
93. Hickie IB, Bansal AS, Kirk KM, et al. A twin study of the etiology of prolonged fatigue and immune activation. Twin Res 2001; 4: 94- 102.
94. Hickie I, Lloyd A, Hadzi-Pavlovic D, et al. Can the chronic fatigue syndrome be defined by distinct clinical features? Psychol Med 1995; 25: 925-35.
95. Broderick G, Fuite J, Kreitz A, et al. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 2010; 24: 1209-17.
96. Hornig M, Gottschalk G, Peterson DL, et al. Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome. Mol Psychiatry 2015;1-9.
97. Lyall M, Peakman M, Wessely S. A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res 2003; 55: 79-90.
98. Mawle AC, Nisenbaum R, Dobbins JG, et al. Immune responses associated with chronic fatigue syndrome: a case-control study. J Infect Dis 1997; 175: 136-41.
99. Chao CC, Janoff EN, Hu SX, et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 1991; 3: 292-8.
100. Bennett AL, Chao CC, Hu S, et al. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J Clin Immunol 1997; 17: 160-6.
101. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
102. Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001; 344: 1846-50.
103. Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 2011; 17: 349-59.
104. Bashashati M, Rezaei N, Andrews CN, et al. Cytokines and irritable bowel syndrome: where do we stand? Cytokine 2012; 57: 201-9.
105. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.
106. Dinan TG, Clarke G, Quigley EM, et al. Enhanced cholinergicmediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol 2008; 103: 2570-6.
107. Bashashati M, Rezaei N, Shafieyoun A, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and metaanalysis. Neurogastroenterol Motil 2014; 26: 1036-48.
108. Bashashati M, Rezaei N, Bashashati H, et al. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2012; 24: 1102-e566.
109. Nickel FT, Seifert F, Lanz S, et al. Mechanisms of neuropathic pain. Eur Neuropsychopharmacol 2012; 22: 81-91.
110. Murphy SL, Phillips K, Williams DA, et al. The Role of the Central Nervous System in Osteoarthritis Pain and Implications for Rehabilitation. Current Rheumatology Reports 2012; 14: 576-82.
111. Lluch E, Torres R, Nijs J, et al. Evidence for central sensitization in patients with osteoarthritis pain: A systematic literature review. Eur J Pain 2014; 18: 1367-75.
112. Brenu EW, van Driel ML, Staines DR, et al. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med 2011; 9: 81.